Mosunetuzumab, a Full-Length Bispecific CD20/CD3 Antibody, Displays Clinical Activity in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (NHL): Interim Safety and Efficacy Results from a Phase 1 Study
Lihua E. Budde(City Of Hope National Medical Center), Nancy L. Bartlett(Washington University in St. Louis), Scott McClellan(Defense Health Agency), Loretta J. Nastoupil(The University of Texas MD Anderson Cancer Center), Vinita Gupta(ESIC Hospital), Youngil Koh(Seoul National University), Raoul Santiago(Jewish General Hospital), Shen Yin, Matthew J. Matasar(Rutgers, The State University of New Jersey), Priya R Kulkarni, Iris Isufi(Yale University), Genevive Hernandez(Sutro Biopharma (United States)), Sarit Assouline(Jewish General Hospital), Chi‐Chung Li, Sung‐Soo Yoon(Seoul National University Hospital), Yu‐Waye Chu, Won-Seog Kim(Samsung Medical Center), Ian W. Flinn(Tennessee Oncology), Bruce McCall, Laurie H. Sehn(BC Cancer Agency)
Cited by 59
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k